Mechanistic Insights Into Cannabidiol-Mediated TrkB Activation via FRS2 Interaction in Attenuating Alzheimer’s Disease Pathology and Cognitive Impairment
A recent preclinical study demonstrates that cannabidiol (CBD) directly engages the TrkB neurotrophin receptor through its PTB‑binding domain, recruiting the adaptor protein FRS2 to trigger robust downstream signaling. This activation attenuates amyloid‑β deposition, tau hyperphosphorylation, and neuroinflammation in transgenic Alzheimer’s disease (AD) mouse models, leading to measurable improvements in spatial and object‑recognition memory. The work provides the first mechanistic link between CBD and TrkB‑FRS2 signaling, positioning CBD as a potential disease‑modifying agent rather than a symptomatic treatment. Results were validated using proteome‑wide target identification and behavioral assays, strengthening translational relevance.
RNA Modifications in Gene Regulation: Functions and Pathways
RNA epigenetics has expanded to over 170 chemically modified nucleotides that shape gene expression at transcriptional and post‑transcriptional levels. The review highlights m6A as the most studied mark, detailing its writer‑METTL3/14 complex, erasers FTO/ALKBH5, and diverse readers that control RNA...
New DNA Base Editor Minimizes Bystander Edits While Maintaining High Efficiency
Researchers at UC San Diego have engineered a minimally evolved adenine base editor (ME‑ABE) that dramatically cuts bystander DNA edits while preserving the high on‑target efficiency of newer ABE8 variants. By reverting five specific mutations in the older ABE7.10 scaffold,...
Prodeon Medical FDA 510(k) Approved for the Urocross Expander System, a Non-Permanent Retrievable Implant for Treating Benign Prostatic Hyperplasia
Prodeon Medical received FDA 510(k) clearance for its Urocross Expander System, a non‑permanent, retrievable implant designed to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. Clinical data from the Expander‑2 randomized trial showed a 48.1% mean improvement in...
After Buying HUB and Partnering with Promega, MilliporeSigma Charts Growth Path in Organoids
MilliporeSigma, the life‑science arm of Merck KGaA, completed its €104 million acquisition of HUB Organoids and has since integrated the business into its Discovery Solutions unit. The company launched a partnership with Promega to develop real‑time reporter assays for organoids, while...
MiniMed Gets FDA Nod for Smaller Insulin Pump
MiniMed, the diabetes‑tech spin‑out of Medtronic, received FDA clearance for its MiniMed Flex insulin pump, a device roughly half the size of the 780G model and operable via smartphone. The pump, featuring a 300‑unit reservoir, targets Type 1 patients aged 7+ and...
Boosting the Blood-Brain Barrier Could Avert Brain Damage in Athletes
Repeated head impacts in contact sports have been linked to lasting damage of the blood‑brain barrier (BBB), a finding that may underlie chronic traumatic encephalopathy (CTE). Researchers scanned 47 retired athletes using an MRI contrast agent that only enters brain...
TerraPower Commits $450M to Build Radioisotope Production Plant
TerraPower Isotopes is committing $450 million to build a cGMP‑compliant actinium‑225 manufacturing plant in Philadelphia, a move that will expand production capacity roughly twenty‑fold. The 250,000‑square‑foot facility, slated to begin output in 2029, will create 225 full‑time jobs and benefits from...
FDA Seeks to Encourage Fewer Animal Studies with New Draft Guidance
The FDA released a draft guidance that details how biopharma firms can validate non‑animal approaches for early‑phase toxicology and safety studies. The document encourages the use of in‑vitro assays, computational modeling, and other modern methods to replace traditional animal testing....
EXoZymes’ Cell-Free Biomanufacturing Platform Gets Positive Feedback From Cayman Chemical
eXoZymes’ cell‑free biomanufacturing platform was independently run by Cayman Chemical at pilot scale, moving from a 1‑L test to a 100‑L reactor. The process produced over 500 g of pharma‑grade N‑trans‑caffeoyltyramine (NCT) with 99.6 % purity and maintained >99 % conversion despite pH...
SBIR Reauthorization, a Top BIO Priority, Is Passed by Congress
Congress passed the reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs on March 17, securing five more years of federal seed funding for biotech startups. The bipartisan House vote was 345‑41 after a...
HDX-MS Plus Computational Methods Provide Novel Approach to Study of Protein-Protein Interactions
Regeneron scientists have integrated hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) with AI‑driven computational analysis to pinpoint binding sites, geometry, and stoichiometry in sandwich ELISA assays. The approach rapidly distinguishes protected versus exposed regions of antibodies, boosting assay specificity and sensitivity. By...
Electrorheoimaging Helps Manage Droplet Viscosity in Real-Time
Researchers at the University of Guelph introduced electrorheoimaging (ERI), a technique that merges electric‑field forcing, rheological measurement, and microscopic imaging to monitor droplet viscosity in real time. By adjusting the frequency of an applied electric field, they achieved instantaneous, reversible...
Benchtop Bioreactor Simplifies Macrophage Manufacturing
Scientists at Hannover Medical School have introduced a standardized protocol that generates macrophages from induced pluripotent stem cells using a 10‑50 mL benchtop bioreactor. The 24‑day workflow produces tens of millions of cells per harvest and allows multiple collections from a...
CAR T Production Bottlenecks Best Tackled with AI, Automation, and Skilled Staff
Patient‑specific CAR‑T therapies face a global production bottleneck due to centralized facilities, manual processes, and high variability in patient cell quality. Researchers highlight that decentralizing manufacturing, eliminating cryopreservation, and accelerating in‑process monitoring can cut vein‑to‑vein times. Automation and artificial intelligence...
STAT+: Clearing Tumors in Mice, Azalea Therapeutics Advances Dream of in Vivo CAR-T Therapy
Azalea Therapeutics, a spinout from Jennifer Doudna’s lab, reported in Nature that its in vivo CAR‑T approach can generate functional CAR‑T cells directly within mice and eradicate both solid and hematologic tumors. The technique uses infused gene‑editing particles that precisely...
Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights
Protagonist Therapeutics received FDA approval for icotrokinra, marketed as Icotyde, becoming the first oral IL‑23 receptor blocker for plaque psoriasis. The clearance arrived ahead of schedule, unlocking a $50 million milestone from Johnson & Johnson and setting up royalty terms of 6‑10% on...
STAT+: A Huntington’s Researcher on the UniQure-FDA Fray
UniQure’s experimental gene‑therapy for Huntington’s disease, which previously reported a 75% slowdown in disease progression, has received a third consecutive rejection from the FDA. The trial’s lead investigator, Ed Wild of University College London, praised the early data but warned...
AI Startup Basecamp Research Announces Trillion-Gene Project
Basecamp Research, an AI‑focused biotech startup backed by Microsoft and Nvidia, announced a trillion‑gene sequencing initiative. The company aims to collect genetic sequences for over a trillion proteins within the next two years. Leveraging high‑performance cloud computing and advanced generative‑AI...
Ionis Delays Prion Disease Readout; Arvinas' Parkinson's Biomarker Data
Ionis Therapeutics announced that the primary completion date for its Phase 1/2a prion disease trial has been pushed to February 2027, extending the study timeline by more than two years. In parallel, Arvinas reported new biomarker data from its Parkinson’s disease program,...
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
Structure Therapeutics reported a 16.3% weight loss after 44 weeks in a Phase 2 trial of its oral GLP‑1 pill, positioning it as a competitive alternative to Eli Lilly’s and Novo Nordisk’s candidates. Rhythm Pharmaceuticals disclosed that its obesity drug Imcivree failed in...
Briggs Morrison's Crossbow Unveils $77M Series B for T Cell Engagers
Crossbow Therapeutics, founded by biotech veteran Briggs Morrison, announced a $77 million Series B round to accelerate its off‑the‑shelf T‑cell engager platform. The funding, led by a mix of venture capital and strategic investors, will support the advancement of three preclinical candidates...
Aspen's Personalized Parkinson's Therapy Shows Early Promise
Aspen Neuroscience reported encouraging early data from a small autologous cell therapy trial for Parkinson's disease. The treatment, derived from each patient's own skin cells and reprogrammed into dopaminergic neurons, was safely implanted in twelve participants, showing graft survival and...
First MHRA/NICE Aligned Guidance Due in June
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) will begin delivering aligned guidance in June, enabling simultaneous licensing and reimbursement decisions for new medicines. Twenty‑seven companies have signed up...
Sanofi’s Venglustat Secures the US FDA Breakthrough Therapy Designation for Type 3 Gaucher Disease
Sanofi’s oral glucosylceramide synthase inhibitor venglustat has earned U.S. FDA breakthrough therapy designation for treating the neurological aspects of type 3 Gaucher disease. The designation follows the Phase III LEAP2MONO trial, which showed significant improvements in motor and cognitive scores compared with...
As Chinese Biotechs Recognize Their Value, the Bargain Era May Be Over
Chinese biotech licensing activity surged in 2025, with 92 deals—a jump from 64 the prior year—and total deal value reaching a record $137.7 billion. The average upfront payment climbed from $102 million to $141 million, signaling that Chinese assets are no longer deep‑discount...
Lilly-Backed China Startup Debuts With $68.7M Seed to Advance Next-Gen T Cell Engagers
Excalipoint Therapeutics, a Shanghai‑based biotech, closed a $68.7 million seed round, including a $41 million founding raise and a $27.7 million extension led by MPCi, Centurium Capital, Lilly Asia Ventures, and Eisai Innovation. The capital will fund six tri‑specific T‑cell engager candidates, notably...
STAT+: J&J Wins Approval for First-of-Its-Kind Psoriasis Pill
Johnson & Johnson received FDA clearance for Icotyde, the first oral daily pill for moderate‑to‑severe plaque psoriasis. The drug, originally called icotrokinra, is approved for patients aged 12 and older and is designed to replicate the efficacy of injectable biologics...
Navigating the Valley of Death: A How-To From an Investor’s Perspective
Biotech startups face the notorious "valley of death" as they move from proof‑of‑concept to commercialization, but investors remain active, with a 70.9% jump in venture‑financing deal value between Q2 and Q3 2025. A GlobalData survey shows 39% of respondents are...
Hope Rises for Vaccine Against Hookworm Parasite
A phase 2 trial of the Na‑GST1/Al–CpG vaccine demonstrated near‑complete protection against hookworm infection in healthy adults, with vaccinated participants shedding a median of zero eggs per gram versus 67 in the placebo group. The study, conducted in Washington, DC,...
Mitochondria Packaged in Blood Cell Membranes Improve Disease Symptoms in Mice
Researchers have engineered microscopic capsules made from red blood cell membranes that encase single, healthy mitochondria and can be injected into animals. In mouse models of Parkinson‑like disease and Leigh syndrome, the capsules restored neuronal function, improved motor activity, and...
New Specifications for Submitting Nucleotide Sequence Data
The International Nucleotide Sequence Database Collaboration (INSDC) has issued new minimal specifications to modernise how nucleotide sequence data and metadata are submitted and exchanged. The framework outlines supported data types, required metadata, linkage rules, and quality checks, creating a unified...
Xaira Unveils AI Model X-Cell for Predicting Virtual Cells
Xaira, the biotech AI startup with the deepest funding round, launched its first model, X‑Cell, on Tuesday. The platform uses deep learning to generate virtual cell representations from multi‑omics data, enabling researchers to simulate cellular responses without physical experiments. Early...
Protein Sequencing Advance Offers New Insights Into Life's Foundations
Stanford bioengineers have unveiled a "reverse translation" chemistry that tags amino acids with DNA barcodes, allowing existing high‑throughput DNA sequencers to read protein sequences. The method achieves single‑molecule sensitivity, potentially analyzing thousands of cells and detecting proteins a thousand times...
START and Trialing Collaborate on Oncology Clinical Trials
START Center for Cancer Research has partnered with Trialing to broaden access to early‑phase oncology clinical trials throughout Europe. The exclusive agreement lets START distribute curated trial information and real‑time enrollment updates via Trialing’s platform, directly notifying oncologists when slots...
Promising Biotechs in Maryland Right Now
Maryland’s life‑science cluster, home to over 2,700 institutions, is projected to generate a $16.7 billion R&D market by 2026. Six home‑grown biotech firms—SciNeuro, Gain Therapeutics, Theriva Biologics, Supernus Pharmaceuticals, Elixirgen Therapeutics and Altimmune—have secured sizable financing and strategic partnerships in the...
The Albumin-Globulin Ratio Mediates Progressive Motor Function Decline in Duchenne Muscular Dystrophy
A retrospective cohort of 201 Duchenne muscular dystrophy (DMD) patients and 202 matched controls revealed that a lower albumin‑globulin ratio (AGR) is strongly associated with poorer motor function and faster loss of ambulation. Logistic and Cox models showed lower AGR...
Co PSMA Prostate Imaging Data Presented at EAU Congress
Clarity Pharmaceuticals presented Phase II Co‑PSMA data at the EAU Congress, showing its 64Cu‑SAR‑bisPSMA PET tracer outperforms the standard 68Ga‑PSMA‑11 in detecting prostate cancer recurrence at low PSA levels. In 50 men post‑radical prostatectomy, 64Cu‑SAR‑bisPSMA identified 63 lesions versus 24...
Cogent Biosciences Reports US FDA’s NDA Acceptance of Bezuclastinib for NonAdvanced Systemic Mastocytosis (NonAdvSM)
Cogent Biosciences announced that the U.S. FDA has accepted its new‑drug application for bezuclastinib in non‑advanced systemic mastocytosis (NonAdvSM), with a PDUFA target date of December 30 2026 and no advisory committee required. The filing is supported by the SUMMIT trial, which...
Ascendis Pharma Reports Topline P-II (New InsiGHTS) Trial Data on TransCon hGH in Turner Syndrome
Ascendis Pharma released topline results from its Phase‑II New InsiGHTS trial evaluating TransCon hGH (lonapegsomatropin) administered once‑weekly versus daily somatropin in 49 prepubertal children with Turner syndrome. At week 52, the weekly formulation achieved an LS mean annualized height velocity...
Salvia Pratensis Exhibits in Vitro Anti-Cancer Effects in Triple-Negative Breast Cancer Through miR-34a-5p Signaling
Researchers evaluated leaf extracts from three Italian plants for activity against triple‑negative breast cancer (TNBC). Salvia pratensis showed the strongest selective effect, cutting viability of MDA‑MB‑231 cells by roughly one‑third while sparing non‑cancerous MCF‑10A cells. The extract triggered mitochondrial reactive...
Rehmannia Glutinosa Polysaccharides: A Review on Structural Features, Pharmacological Potential, and Advanced Delivery Systems
The review highlights Rehmannia glutinosa polysaccharides (RGPs) as multifunctional heteropolysaccharides with immunomodulatory, anti‑inflammatory, antitumor, anti‑aging, and metabolic benefits. It details how structural attributes—molecular weight, monosaccharide composition, and glycosidic linkages—drive these activities and why poor oral bioavailability and batch variability impede...
Voro Therapeutics Collaborates with Daiichi Sankyo to Develop Tumor-Activated ADCs
Voro Therapeutics has signed a research collaboration with Daiichi Sankyo’s San Diego research institute to create tumor‑activated antibody‑drug conjugates (ADCs) using Voro’s PrimeBody platform. The partnership will focus on masked ADCs that employ proprietary masking domains and protease‑cleavable linkers to achieve...
Chinese Scientists Use E Coli to Fight Breast Tumours From Within in Mice Study
Chinese researchers at Shandong University have engineered the probiotic strain Escherichia coli Nissle 1917 to synthesize and deliver the anticancer drug Romidepsin directly within breast‑tumor tissue in mice. The bacteria colonized the tumors, releasing the drug locally and achieving tumor‑inhibiting...
Xoma Royalty Corp (XOMA) Q4 2025 Earnings Call Transcript
Zymeworks reported Q4 2025 revenue of $106 million, up from $76.3 million, while net loss narrowed to $81.1 million as operating expenses fell. The company highlighted Phase III zanidatumab data showing median PFS over one year and overall survival beyond two years in first‑line...
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
Zymeworks will present Phase 1 data on its folate‑receptor‑alpha ADC ZW191 and preclinical results for a novel pan‑RAS inhibitor ADC platform at the AACR Annual Meeting. The oral presentation will detail dose‑escalation safety and efficacy in advanced solid tumours, while...
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals announced that two preclinical abstracts on its PRC2‑targeting agent rinzimetostat (ORIC‑944) have been accepted for poster presentation at the 2026 AACR Annual Meeting. The data show rinzimetostat, an allosteric EED inhibitor, maintains potency against EZH1‑overexpressing complexes and key...
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel Dual-Target MUC16/NaPi2b Tetravalent ADC ARR-002...
ArriVent BioPharma will showcase two preclinical posters at the 2026 AACR Annual Meeting, highlighting its EGFR inhibitor firmonertinib and the dual‑target tetravalent ADC ARR-002. Firmonertinib demonstrates high‑potency inhibition of both classical EGFR mutations and exon‑20 insertion variants, with strong brain...
Graphene Sensors Stay Stable in Liquids, Boosting Sensitivity up to 20 Times
Researchers at Penn State have unveiled a dual‑gate graphene field‑effect transistor that remains stable in liquid environments, eliminating the signal drift that hampers conventional sensors. By pairing a high‑capacitance top gate with a low‑capacitance bottom gate and adding a feedback...
Webinar: Operationalizing AI in Drug Development: Inside DIA’s Global AI Consortium
The Drug Information Association (DIA) has launched a public‑private AI Consortium that unites regulators, biopharma, academia, and technology firms to shape AI governance in drug development. The group is developing a seven‑step classification framework that aligns AI use‑cases with risk‑proportionate...
